Official Title Mobile Health App as a Cardiotoxicity Symptom Logging Tool: Feasibility Pilot Study

Purpose

To evaluate the cardio-oncology patient population’s experience with using smart-phone technology as a part of self-management with their care through features such as symptom logging and education. Eligible patients will be asked to participate in a 30-minute virtual interview and/or a 60-minute virtual design or usability session to discuss their thoughts on a mobile app for cardio-oncology patients.

Could this study be right for you?

• English-speaking
• Prior cancer diagnosis
• Currently undergoing a cancer regimen that includes a targeted, biologic, radiation, and/or immune-based therapy (e.g., TKIs and/or ICIs).
• No pregnant females
• No prisoners

Age Range

18 and up

Official Title Immune Response in Adolescents

Purpose

Our goal in this study is to learn more about the immune system in adolescence and early adulthood. We are looking to enroll healthy children ages 12-18 years old.

Enrollment in the study will require 1 visit to Nationwide Children’s Hospital involving a blood draw and 2 nasal swabs.
The visit will take approximately 1- 1 ½ hour(s). We ask that the family brings a copy of the child’s immunization record to the visit.

Could this study be right for you?

Children will need to meet the following criteria to be in the study:

Inclusion Criteria:

• Parents/Legal guardian able and willing to sign informed consent and the child is willing to sign assent form for participation. All forms are in English.
• Healthy children, age 12-18 years old

Exclusion Criteria:

• Any chronic or congenital conditions that may potentially affect immune responses
• Cough, congestion, fever, rhinorrhea, rash and any other symptoms indicative of infection within the 2 weeks prior to enrollment sampling
• HIV, AIDS or other immunodeficiencies or any other condition that may affect their immune system
• Use of systemic steroids within 2 weeks prior to enrollment
• Immunization(s) within the last 30 days

Age Range

12 and up

Official Title ImproviNg The BrEast CaNcer Care DelivEry MoDel for Sex and Gender Minority Survivors (INTENDED for SGM)

Purpose

The long-term goal of this study is to improve decision quality and health-related outcomes for sexual gender minority (SGM) breast/chest cancer survivors. The goal is to evaluate important ways the current care model needs adjusted for SGM people, and how best to combine a socially important care model into clinical practice.

Survivors: Eligible participants will participate in a 90-minute focus group and online survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

Clinicians: Eligible participants will participate in a 30-minute interview and brief survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

Participation in this study will take no more than 1 hour and 30 minutes.

Could this study be right for you?

Survivors:

1. Self-identify as a member of the SGM community
2. Age ≥18 years at the time of signing the informed consent form
3. Breast/chest cancer survivor in active treatment or completed active treatment in the last 10 years (not including hormone therapy)
4. Be able to read and speak English
5. Have received care in the U.S.
6. Be able to participate in virtual meetings

Clinicians:

1. Physicians, advance practice providers, nurses, psychologists, social workers, therapists, technologists, and other trained clinical professionals
2. Provide care to individuals diagnosed with breast cancer in the U.S.
3. Be able to read and speak English
4. Be able to participate in virtual meetings

Age Range

18 and up

Official Title A Hybrid Effectiveness-Implementation Trial to Improve Safe Driving among Teen Drivers with Traffic Violations

Purpose

The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent training, on parent-teen communications as well as teens' risky driving behaviors, unsafe driving behaviors, and subsequent traffic violations.

Could this study be right for you?

In order to be eligible:

• You must be 16-18 years of age
• Need a valid State of Ohio driver's license (no learner's permit)
• Proof of car insurance
• Must drive more than one hour per week

Age Range

16 and up

Official Title A Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) experiencing REM sleep behaviors (RBD)

Purpose

The purpose of this study is to evaluate the safety of the study drug called nelotanserin and to assess the effects of nelotanserin in those experiencing frequent REM sleep behavior disorders due to dementia with Lewy bodies. Nelotanserin (study drug) is an investigational product, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) or the government health agencies of any other countries.

Could this study be right for you?

• Age: 50-85
• Diagnosis: probable dementia with Lewy bodies or Parkinson's disease dementia
• AND diagnosis of REM sleep behavior disorder (RBD) with frequent RBD episodes
• Must have a study partner willing to serve as a collateral informant for study assessments
• MMSE Score: greater than or equal to 18 (Mini Mental State Examination score to be explained by the coordinator)

Age Range

50 and up

Official Title Movement and Music Intervention for Individuals with Dementia

Purpose

There is some evidence that music based interventions may have a protective effect on the brain in those with dementia. There is also evidence that doing activities that engage the brain through music are beneficial. This study seeks to investigate the potential benefits of a music based intervention for individuals with dementia.

Could this study be right for you?

You may be eligible if you:

• Have a diagnosis of dementia (mild to moderate)
• Are age 60 and older
• Able to follow simple instructions

EXCLUSION CRITERIA:

• Unable to walk 10 feet unassisted
• Presence of bone disorder that impacts walking
• Presence of other neurologic diagnosis that impacts cognitive or motor function such as stroke, Parkinson disease or traumatic brain injury

Age Range

60 and up

Official Title Perinatal Arterial Stroke: The I-ACQUIRE Study

Purpose

Children who suffered a stroke before or shortly after being born that was caused by blockage of blood flow in an artery, it often results in the child showing some weakness on one side of their body.

With this study, we want to find out if a type of therapy may help children who have weakness on one side of their body due to perinatal arterial ischemic stroke, learn how to better use their weaker arm.

All children will be in the study for about 13 - 15 months. Some children may be in the study for a longer period, depending on which treatment they receive during Phase 1 of the study. The I-ACQUIRE therapy involves fun learning and play, self-help activities, and manipulating interesting toys and objects.

Could this study be right for you?

• Your child must be between the ages of 8 and 36 months old when beginning this study
• Your child must have suffered a perinatal arterial ischemic stroke
• Upper limb weakness
• Parents must be able to participate at least 1x/week for therapy and 40-60 minutes/day at home

Official Title Shoulder Surgery Outcomes Registry

Purpose

This registry will collect outcomes data of patients undergoing shoulder surgery with Dr. Jonathan Barlow or Dr. Julie Bishop. The purpose of this registry is to provide a way to collect and store data for patients undergoing shoulder surgery to support the conduct of future research in an effort to improve patient outcomes.

Could this study be right for you?

• A patient undergoing surgery with Dr Jonathan Barlow or Dr Julie Bishop (will be asked to enroll once the clinical decision has been made to proceed with surgery)
• 18 to 89 years old
• Able to provide consent

Age Range

18 and up

Official Title A prospective, single blinded, multi-center, randomized, controlled, pivotal study to assess the safety and effectiveness of the InSpace™ device for treatment of full thickness Massive Rotator Cuff Tears

Purpose

This research study will evaluate a new device, InSpace, for use with a full thickness massive tear of rotator cuff (the group of connective tissues in the shoulder). The device is designed to allow smooth gliding of the bones in the shoulder during motion, which may allow rehabilitation exercises with less pain. The research study is being conducted to see whether the InSpace device is safe and effective for shoulder problems due to a full thickness massive rotator cuff tear.

Could this study be right for you?

1. Is male or female ≥ forty (40) years of age
2. Positive diagnostic imaging by MRI within 9 months of enrollment of the index shoulder indicating a full thickness MRCT: measuring ≥ 5 cm in diameter (Cofield classification) and involving ≥ two tendons
3. Functional deltoid muscle and preserved passive range of motion on physical examination
4. Failed non-operative treatment of at least 4 months from the initial treatment to include one or all of the following: Oral analgesics, Anti-inflammatory medication (e.g., ibuprofen, naproxen), Corticosteroid injection(s), Physical therapy, Activity modification, or Rest (sling used)
5. Must be able to read and understand the approved Informed Consent Form (written and oral)
6. Must be in general good health (as determined by the Investigator) based on screening assessments and medical history
7. Must be independent, ambulatory, and can comply with all post-operative evaluations and visits.

Other details will be shared by the study coordinator.

Age Range

40 and up

Official Title AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)

Purpose

The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes.

Could this study be right for you?

• You are at least 45 years old
• Clinical diagnosis of ischemic stroke* of unknown cause (ESUS or cryptogenic) in the last 120 days
• Underwent an echocardiogram as part of your stroke work up
• No history of atrial fibrillation (irregular heartbeat)
• No known allergy or intolerance to aspirin or apixaban

*An “ischemic” stroke is an injury to the brain caused by a blocked blood vessel supplying the brain.

Age Range

45 and up

Official Title The Ohio State Lupus, Vasculitis and Glomerulonephritis Registry

Purpose

The purpose of the OSU Lupus and Vasculitis Registry is to obtain clinical and laboratory information about lupus and vasculitis and glomerulonephritis.

Could this study be right for you?

Patients at the Ohio State University Rheumatology and Lupus Clinic with one of the following diagnoses who are ages 18 years of age and older:

• Systemic lupus erythematosus
• Discoid lupus
• Mixed connective tissue disorder
• Undifferentiated connective tissue disorder
• Wegener’s granulomatosus
• Microscopic polyangiitis
• Henoch-Schonlien Purpura
• Takayasu’s arteritis
• Giant cell/temporal arteritis
• Churg-Strauss vasculitis
• Other vasculitides
• IgA nephropathy
• Anti-GBM GN
• Membranous GN
• Minimal Change Disease
• Focal Segmental Glomerulosclerosis

Age Range

18 and up

Official Title A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

Purpose

This research study is for those who have nonalcoholic steatohepatitis (NASH) (meaning your liver is swollen and damaged because of a buildup of fat in your liver) and some liver fibrosis (which is damaged and scarred liver tissue). Because of your condition, you may be eligible for a research study on an investigational drug for your condition. The Regenerate Study will assess the safety and effectiveness of the investigational medication obeticholic acid (OCA) compared to placebo in delaying specific medical conditions or health related issues that can occur in patients with nonalcoholic steatohepatitis (NASH) (meaning your liver is swollen and damaged because of a buildup of fat in your liver) and some liver fibrosis (which is damaged and scarred liver tissue).

Could this study be right for you?

• Age 18 or older
• Diagnosed with Stage 2 or 3 NASH (nonalcoholic steatohepatitis--meaning your liver is swollen and damaged because of a buildup of fat in your liver) and some liver fibrosis (which is damaged and scarred liver tissue).

If you are eligible and decide to take part in this research study, you will need to complete 1 or 2 screening visits to see if you are eligible to participate in the study. Once the study doctor determines you can participate in the study, you will be asked to come back to the clinic 8 times (for the Month 0 [Day 1] Visit, the Month 1 Visit, the Month 3 Visit, and then every 3 months) for the first 18 months you are in the study and then 2 times per year (every 6 months) for each additional year you are in the study.

Age Range

18 and up